Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies (HEART)

September 25, 2023 updated by: University Hospital, Ghent

Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth in Twin Pregnancies

In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.

Study Overview

Detailed Description

Fetal growth restriction (FGR) is diagnosed in 5-10% of the pregnancies. After preterm birth, it is the second leading cause of perinatal morbidity and mortality. Twin pregnancies have a higher occurrence of FGR than singletons, in monochorionic (MC) twin pregnancies it's diagnosed in 19.7% of the cases and in dichorionic (DC) twin pregnancies in 10.5% of the cases. Fetuses with FGR are at greater risk of perinatal morbidity and mortality and even long-term health defects. From a public health perspective, it's important to correctly diagnose FGR to adjust the antenatal and postnatal care and to have more insight into the factors influencing early onset cardiovascular disease. STE has a strong predictive value for cardiovascular function, therefore it would be a promising tool to add in the routine pregnancy clinical care. Speckle tracking echocardiography (STE) is a relative new technique especially in the pregnancy follow up, which permits offline calculation of myocardial velocities and deformation parameters. These parameters, including strain and strain rate, provide information about the fetal myocardial function. Apart from investigating if STE can be used for the prediction of FGR, we will also investigate the association between fetal exposure to air pollution and in utero cardiac remodeling. Indeed, it is known that inhalation of particulate matter (e.g. black carbon) during the pregnancy can reach the placenta and lead to alterations in the placenta's function including increases in oxidative stress markers. Early life exposure to black carbon has been associated with adverse cardiovascular health outcomes and reduction of fetal growth, especially in multiple gestation pregnancies.

In this project we will include 2 time points during the pregnancy, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 20 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.

Study Type

Observational

Enrollment (Estimated)

360

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Ghent, Belgium, 9000
        • Recruiting
        • Ghent University Hospital
        • Contact:
          • Kristien Roelens, prof. dr.
      • Leuven, Belgium, 3000
        • Not yet recruiting
        • Universitair Ziekenhuis Leuven
        • Contact:
          • Liebeth Lewie, prof. dr.
      • Eindhoven, Netherlands, 5631
        • Not yet recruiting
        • Maxima Medical Center
        • Contact:
          • Judith van Laar, dr.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

The number of subjects that will be included in this study is: 600 neonates (200 twin pairs and 200 singletons) and 400 pregnant mothers.

The fetuses are divided into following sub-groups:

  • Appropriately grown
  • Fetal growth restricted
  • Selective fetal growth restricted (specific for twins)

Description

Inclusion Criteria:

  • Singleton or dichorionic twin pregnancy
  • Pregnant women 21 weeks ( ± 2 weeks) of gestation at the first visit
  • Women ≥ 18 years

Exclusion Criteria:

  • Women pregnant of multiples of higher order (≥3 siblings) Monochorionic twin pregnancy
  • Fetal arrhythmia
  • Known fetal congenital or genetic abnormalities
  • Any suspicion of congenital fetal anomalies that might influence fetal cardiac function
  • Pre-existing maternal hypertensive disease
  • Autoimmune disease including systemic lupus erythematosus
  • History of stillbirth
  • Diabetes mellitus (mother)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Fetal growth restricted
Observation of cardiac remodeling perinatal and postnatal
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
Appropriately grown
Observation of cardiac remodeling perinatal and postnatal
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the change in strain measured by speckle tracking echocardiography as a tool for early diagnosis of impaired fetal growth in multiple gestations
Time Frame: Prenatal to 1-3 days after birth
to determine the change in fetal strain and strain rate in twin pregnancies in comparison with fetal growth
Prenatal to 1-3 days after birth
To determine the intra-pair differences in fetal growth and strain (cardiac remodeling) in multiple gestations.
Time Frame: Prenatal to 1-3 days after birth
to compare changes in strain and strain rate with fetal growth within 1 twin pair
Prenatal to 1-3 days after birth
To compare the strain values (cardiac remodeling) between singletons and twin pregnancies
Time Frame: Prenatal to 1-3 days after birth
to compare the changes in strain and strain rate between singletons and twin pregnancies
Prenatal to 1-3 days after birth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To investigate the association between placenta functioning and in utero cardiac remodeling
Time Frame: Prenatal to 1-3 days after birth
to evaluate placenta insufficiency (Doppler ultrasound, biochemical marker) with strain and strain rate
Prenatal to 1-3 days after birth
To explore in utero cardiac remodeling in association with neonatal cardiovascular health
Time Frame: Prenatal to 1-3 days after birth
to evaluate strain and strain rate with the neonatale blood pressure and heart rate
Prenatal to 1-3 days after birth
To study the association between prenatal air pollution exposure and in utero cardiac remodeling
Time Frame: Prenatal to 1-3 days after birth
to evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with strain and strain rate
Prenatal to 1-3 days after birth
To investigate placenta functioning as a mediator between air pollution and cardiac remodeling
Time Frame: Prenatal to 1-3 days after birth
To evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with placenta insufficiency (biochemical marker, Doppler ultrasound)
Prenatal to 1-3 days after birth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kristien Roelens, University Hospital, Ghent

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 22, 2023

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2028

Study Registration Dates

First Submitted

May 31, 2022

First Submitted That Met QC Criteria

June 14, 2022

First Posted (Actual)

June 21, 2022

Study Record Updates

Last Update Posted (Actual)

September 26, 2023

Last Update Submitted That Met QC Criteria

September 25, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Air Pollution

Clinical Trials on sample collection

Subscribe